文献速递妇产影像技术与安全US

STATIN试验:竞争风险模型在35-37周妊娠筛查子痫前期的预测性能

STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

本研究基于STATIN研究筛查人群的前瞻性多中心数据,验证既往报道的竞争风险模型在35-37周妊娠筛查子痫前期的预测性能。模型组合孕妇风险因素、平均动脉压、胎盘生长因子和可溶性fms样酪氨酸激酶-1,在10%假阳性率下检出率为79%(95%CI 76-82%),AUC为0.923(95%CI 0.913-0.932),校准斜率为0.875(95%CI 0.831-0.919),显示良好区分度和校准度。

要点

  • 联合孕妇风险因素、MAP、PlGF和sFlt-1的三联检测在10%假阳性率下对35-37周子痫前期检出率达79%。
  • 加入子宫动脉搏动指数未改善三联检测的预测性能。
  • 模型AUC为0.923,校准斜率为0.875,预测风险与观察发生率一致性良好。

局限性

  • 研究基于STATIN试验筛查人群,模型验证可能受人群选择影响。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To examine the predictive performance of a previously reported competing-risks model of screening for pre-eclampsia (PE) at 35-37 weeks' gestation by combinations of maternal risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1) in a validation dataset derived from the screened population of the STATIN study.

METHODS: This was a prospective third-trimester multicenter study of screening for PE in singleton pregnancies by means of a previously reported algorithm that combines maternal risk factors and biomarkers. Women in the high-risk group were invited to participate in a trial of pravastatin vs placebo, but the trial showed no evidence of an effect of pravastatin in the prevention of PE. Patient-specific risks of delivery with PE were calculated using the competing-risks model, and the performance of screening for PE by maternal risk factors alone and by various combinations of risk factors with MAP, UtA-PI, PlGF and sFlt-1 was assessed. The predictive performance of the model was examined by, first, the ability of the model to discriminate between the PE and no-PE groups using the area under the receiver-operating-characteristics curve (AUC) and the detection rate at a fixed false-positive rate of 10%, and, second, calibration by measurements of calibration slope and calibration-in-the-large.

RESULTS: The study population of 29 677 pregnancies contained 653 that developed PE. In screening for PE by a combination of maternal risk factors, MAP, PlGF and sFlt-1 (triple test), the detection rate at a 10% false-positive rate was 79% (95% CI, 76-82%) and the results were consistent with the data used for developing the algorithm. Addition of UtA-PI did not improve the prediction provided by the triple test. The AUC for the triple test was 0.923 (95% CI, 0.913-0.932), demonstrating very high discrimination between affected and unaffected pregnancies. Similarly, the calibration slope was 0.875 (95% CI, 0.831-0.919), demonstrating good agreement between the predicted risk and observed incidence of PE.

CONCLUSION: The competing-risks model provides an effective and reproducible method for third-trimester prediction of term PE. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Döbert M, Wright A, Varouxaki AN, et al. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2022. PMID: 34580947. doi:10.1002/uog.24789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。